Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene for Breast Cancer Prevention in High-Risk Premenopausal Women
NCT00019500Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raloxifene in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and Tolerability at 2 years. Started Dec 1998; status: completed.
02
Drugs
raloxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00019500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019500.